CDR209: A Novel TRBV9×CD3 T Cell Engager for Precision Depletion of Disease-Associated T Cells in Axial Spondyloarthritis (ACR Convergence 2026) - Oct 16, 2026 - Abstract #LB01; Pres time: Nov 10, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; "These findings demonstrate that CDR209 enables highly selective depletion of TRBV9-positive T cells while preserving the broader T cell repertoire. The favorable safety and translational profile support further development of CDR209 as a potential first-in-class precision therapeutic for axSpA. Figure."
Late-breaking abstract • Ankylosing Spondylitis • Axial Spondyloarthritis • Immunology • Seronegative Spondyloarthropathies • Spondylarthritis • CD20 • CD69 • GZMB • TRB
|
|
Anna Sobieraj; Athanasia Dasargyri; Philipp Richle; Fabian Scheifele; Stephanie Jungmichel; Hannes Merten; Romina Doerig; Martina Priola; Blaz Pavlovic; Zoi Barou; Ariadna Vilarrasa; Loredana Iuliano; Cedric Kiss; Luca Scheu; Anna-Maria Evangelopoulou; Alessio Vantellini; Nora Wettstein; Alice Langer; Christian Leisner and Leonardo Borras
|